Aptose Biosciences (NASDAQ:APTO) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $23.00 price objective on the biotechnology company’s stock.

Other analysts also recently issued research reports about the company. StockNews.com downgraded Aptose Biosciences from a hold rating to a sell rating in a research report on Monday, March 18th. Piper Sandler lowered their price target on Aptose Biosciences from $12.00 to $5.00 and set an overweight rating on the stock in a research report on Thursday, February 1st. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus price target of $19.80.

Aptose Biosciences Stock Performance

NASDAQ:APTO opened at $1.66 on Wednesday. The stock’s 50-day simple moving average is $1.81 and its 200 day simple moving average is $2.34. The company has a market cap of $26.10 million, a P/E ratio of -0.22 and a beta of 1.30. Aptose Biosciences has a 52-week low of $1.36 and a 52-week high of $9.90.

Hedge Funds Weigh In On Aptose Biosciences

A number of institutional investors have recently bought and sold shares of APTO. Sequoia Financial Advisors LLC acquired a new position in Aptose Biosciences during the first quarter worth approximately $27,000. Renaissance Technologies LLC grew its position in shares of Aptose Biosciences by 3.6% in the first quarter. Renaissance Technologies LLC now owns 976,577 shares of the biotechnology company’s stock valued at $1,328,000 after purchasing an additional 33,952 shares during the last quarter. Cetera Advisors LLC grew its position in shares of Aptose Biosciences by 40.1% in the fourth quarter. Cetera Advisors LLC now owns 86,827 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 24,847 shares during the last quarter. Millennium Management LLC grew its position in shares of Aptose Biosciences by 75.4% in the fourth quarter. Millennium Management LLC now owns 222,930 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 95,796 shares during the last quarter. Finally, Annandale Capital LLC grew its position in shares of Aptose Biosciences by 12.7% in the fourth quarter. Annandale Capital LLC now owns 800,000 shares of the biotechnology company’s stock valued at $464,000 after purchasing an additional 90,000 shares during the last quarter. Institutional investors and hedge funds own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.